The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000805370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
11/02/2026
Date registered
Help: Date registered
6/07/2026
Date last updated
Help: Date last updated
6/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
6/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A First-in-Human Study to Assess the Safety of a New Investigational Medicine (MQ005) in Adults with Sepsis
Scientific title
An Open-Label Phase 1 Study of Single Ascending Doses of MQ005 to Assess Safety and Tolerability in Adults with Sepsis
Additional trial identifiers [1] 316385 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Sepsis 340477 0
Condition category
Condition code
Infection 336684 336684 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
MQ005 is a recombinant, fully human IgM monoclonal antibody targeting straight chain poly-N-acetyllactosamine (scPNAL) on specific immune cells. It is administered intravenously over approximately 30 minutes using an infusion pump with a 0.2 µm inline filter, followed by a 10 mL normal saline flush. Doses are weight-based by cohort (0.2, 0.5, 1.0, 2.0, or 4.0 mg/kg), with a capped maximum dose of 400 mg for subjects weighing more than 100 kg.

The study uses a sentinel and cohort-based dose escalation design. Each cohort begins with a sentinel subject who receives a single dose. Subsequent subjects in that cohort may begin dosing only after a 72-hour safety review of the sentinel subject has been completed and no safety signals are identified in the opinion of the investigator. Subsequent subjects may receive once-daily dosing for up to five total daily doses, provided there are no new immunologic adverse events and the subject’s clinical status has not worsened.

MQ005 is administered by trained clinical staff at the study site. Adherence is ensured through direct administration and observation, with infusion start and stop times, dosing windows (±1 hour), and dose completion recorded in source documentation and case report forms. Drug preparation and accountability are managed according to the Pharmacy Manual.

No other investigational or immunomodulatory agents are permitted during the study, except standard-of-care treatments for sepsis (including corticosteroids when clinically indicated). Safety monitoring includes clinical assessments, laboratory testing, electrocardiograms, and adverse event reporting through Day 28.
Intervention code [1] 333050 0
Treatment: Drugs
Description of the comparator or control
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344194 0
Treatment-emergent adverse events (TEAEs)
Timepoint [1] 344194 0
Continuously monitored from first dose through Day 28 post-first dose.
Primary outcome [2] 344477 0
Dose-limiting toxicities (DLTs) as defined in the protocol.
Timepoint [2] 344477 0
Continuously monitored from first dose through Day 14 post-first dose.
Primary outcome [3] 344478 0
Changes in clinical laboratory parameters, vital signs, cardiorespiratory status, and immunogenicity (anti-MQ005 antibodies).
Timepoint [3] 344478 0
Laboratory parameters and vital signs: baseline and daily during hospitalisation through Day 7 post-first dose, with continued safety assessments through Day 28 as per Schedule of Assessments. Immunogenicity: Baseline, Day 14, and Day 28 (±2 days) post-first dose.
Secondary outcome [1] 457019 0
Pharmacokinetics of MQ005 following single-dose administration.
Timepoint [1] 457019 0
Pre-dose (within 48 hours prior to the first dose); immediately post end-of-infusion (~30 minutes); and at 1, 2, 4, 8, 12, and 24 hours following the first dose. For participants who receive optional repeat dosing (Days 2–5, where applicable), pre-dose trough samples will be collected before each repeat dose. Follow-up samples will be collected at 48 hours (±4 hours), 72 hours (±4 hours), Day 14 (±1 day), and Day 28 (±2 days) following the final administered dose.
Secondary outcome [2] 458925 0
Pharmacokinetics of MQ005 following repeat-dose administration (once daily dosing for up to 5 days).
Timepoint [2] 458925 0
Pre-dose trough samples on repeat dosing days (Days 2–5, where applicable); immediately post end-of-infusion (~30 minutes); and follow-up samples collected at 48 hours, 72 hours, Day 14, and Day 28 following the final dose.
Secondary outcome [3] 459487 0
Immunogenicity of MQ005 following single and any repeat dosing.
Timepoint [3] 459487 0
Baseline, Day 14 (±2 days), and Day 28 (±2 days) post-first dose. For subjects with confirmed treatment-emergent ADA at Day 28 post-first dose: follow-up testing at approximately Day 60 and Day 90 post-first dose, with possible extension to Day 180 post-first dose if ADA remains persistent or clinically relevant.

Eligibility
Key inclusion criteria
1. At least 18 years of age at the time of signing the Informed Consent Form (ICF)
2. Sepsis (including septic shock) defined according to the Sepsis-3 criteria (suspected or documented infection and an acute increase of greater than or equal to 2 points in the Sequential Organ Failure Assessment (SOFA) score)
3. Serum lactate greater than or equal to 2.0 mmol/L and serum procalcitonin greater than or equal to 0.5 ng/mL
4. Subjects or duly authorized representatives are willing and able to give informed consent.
5. Not planning for pregnancy in next 12 months. If male no pregnancy of partner planned for 90 days
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Sepsis that is beyond resuscitation in the opinion of the investigator
2. History of hematologic disorders, autoimmune hemolytic anemia, or previous positive anti-i antibody test (if known)
3. History of anaphylaxis to prior immunotherapy
4. Prior diagnosis of systemic lupus erythematosus
5. Subject is pregnant or breastfeeding
6. Subject is unwilling to allow transfusion of blood or blood products
7. Presence of an advance directive to withhold life-sustaining treatment
8. Organ transplant recipients
9. Severe chronic kidney disease or end-stage renal disease (ESRD), including any current renal replacement therapy (hemodialysis, peritoneal dialysis, or CRRT)
10. Confirmed or suspected endocarditis
11. End-stage neurological disorders (e.g., amyotrophic lateral sclerosis)
12. Life expectancy is less than 4 weeks in the opinion of the investigator

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 320998 0
Commercial sector/Industry
Name [1] 320998 0
Mcure Biosciences Pty Ltd
Country [1] 320998 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Mcure Biosciences Pty Ltd
Address
Country
United States of America
Secondary sponsor category [1] 323696 0
Commercial sector/Industry
Name [1] 323696 0
Avance Clinical Pty Ltd
Address [1] 323696 0
Country [1] 323696 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319530 0
Monash Health Human Research Ethics Committee A
Ethics committee address [1] 319530 0
Ethics committee country [1] 319530 0
Australia
Date submitted for ethics approval [1] 319530 0
07/01/2026
Approval date [1] 319530 0
25/05/2026
Ethics approval number [1] 319530 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147622 0
Prof Yahya Shehabi
Address 147622 0
Monash Health, Monash Medical Centre, E Block, Level 5, 246 Clayton Road, Clayton, VIC, 3168
Country 147622 0
Australia
Phone 147622 0
+61419296986
Fax 147622 0
Email 147622 0
Contact person for public queries
Name 147623 0
Yahya Shehabi
Address 147623 0
Monash Health, Monash Medical Centre, E Block, Level 5, 246 Clayton Road, Clayton, VIC, 3168
Country 147623 0
Australia
Phone 147623 0
+61419296986
Fax 147623 0
Email 147623 0
Contact person for scientific queries
Name 147624 0
Yahya Shehabi
Address 147624 0
Monash Health, Monash Medical Centre, E Block, Level 5, 246 Clayton Road, Clayton, VIC, 3168
Country 147624 0
Australia
Phone 147624 0
+61419296986
Fax 147624 0
Email 147624 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.